Related references
Note: Only part of the references are listed.Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm
Akira Sawaki et al.
GASTRIC CANCER (2018)
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
Josep Tabernero et al.
LANCET ONCOLOGY (2018)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. C. Smyth et al.
ANNALS OF ONCOLOGY (2016)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
Y-K Kang et al.
BRITISH JOURNAL OF CANCER (2014)
Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA
Sandra M. Swain et al.
ONCOLOGIST (2014)
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel
Javier Cortes et al.
ANTI-CANCER DRUGS (2013)
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
Akira Sawaki et al.
GASTRIC CANCER (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Share Paper
